Global Duchenne Muscular Dystrophy Treatment Market, By Treatment Type (Molecular-Based Therapies, Steroid Therapy, and Others), Therapy (Exon Skipping Approach, Mutation Suppression, and Dystrophin-Targeted Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.
Duchenne Muscular Dystrophy Treatment Market Analysis and Size
The primary factors expected to drive the market growth are the rising awareness of DMD treatment and the introduction of novel therapies for DMD disorder. In addition, rising prevalence and impact of DMD disorder are another key driver expected to drive market growth. A rise in the number of clinical trials is a recent trend is also expected to drive the market growth. However, the limited availability of DMD treatment due to advanced technology and the high treatment cost of DMD disorder are expected to restrain market growth.
Data Bridge Market Research analyzes that the global duchenne muscular dystrophy treatment market is expected to reach USD 8,654,688.51 thousand by 2030, at a CAGR of 16.8% during the forecast period 2023-2030. This market report also covers pricing analysis and technological advancements in depth.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Treatment Type (Molecular-Based Therapies, Steroid Therapy, and Others), Therapy (Exon Skipping Approach, Mutation Suppression, and Dystrophin-Targeted Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Sarepta Therapeutics, Inc., GSK plc., Capricor Therapeutics, Inc., Dyne Therapeutics, Solid Biosciences Inc., BioMarin, Stealth BioTherapeutics Inc., Avidity Biosciences, ReveraGen BioPharma, Inc. PTC Therapeutics., NS Pharma, Inc, ITALFARMACO S.p.A., FibroGen, Inc, SANTHERA PHARMACEUTICALS, Pfizer Inc., F. Hoffmann-La Roche Ltd, Akashi RX, and TAIHO PHARMACEUTICAL CO., LTD and among others
|
Market Definition
Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration and weakness. The primary treatment for DMD involves the use of corticosteroids, such as prednisone or deflazacort. These medications help reduce inflammation and delay muscle degeneration, ultimately prolonging the ability to walk and preserving muscle function. Corticosteroid treatment has been shown to improve muscle strength, respiratory function, and overall quality of life in individuals with DMD.
Global Duchenne Muscular Dystrophy Treatment Market Dynamics
This section deals with understanding the market drivers, advantages, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Prevalence and Impact of Duchenne Muscular Dystrophy (DMD) disease
Duchenne Muscular Dystrophy (DMD) is a rare and debilitating genetic disorder characterized by progressive muscle weakness and loss of function. It primarily affects males, with symptoms typically appearing in early childhood. The number of individuals diagnosed with DMD is also increasing, and this rising prevalence has created a need for effective treatments and therapies, as the global population continues to grow.
The rising prevalence of DMD has also increased advocacy efforts by patients and healthcare professionals. These groups play a vital role in raising awareness about DMD, advocating for research funding, and faster approvals of potential treatments. The DMD community is rising, therefore, the advancement of technologies and investments in this area of healthcare is also
- Introduction of Novel Therapies for DMD Disorder
The emergence of innovative treatment approaches leads to rise in DMD care and contributing significantly to market expansion. Traditional treatment options primarily focused on symptom management and supportive care. However, the introduction of novel therapies represents a paradigm shift as they aim to address the root genetic mutations responsible for DMD.
Moreover, exon-skipping drugs have emerged as another promising class of therapies for DMD. These drugs are designed to "skip" specific exons in the dystrophin gene, allowing for the production of a truncated but partially functional dystrophin protein. These drugs can significantly slow the progression of the disease and improve the quality of life for individuals with DMD. The development and approval of these therapies have provided renewed expectations to DMD patients and is further expected to drive market growth.
Opportunity
- Development of Healthcare Infrastructure and Increasing Investment
Patients with DMD can be diagnosed earlier with a stronger healthcare infrastructure, including well-equipped hospitals and diagnostic facilities. Early diagnosis allows for timely intervention and the initiation of treatment, potentially slowing disease progression and improving patient outcomes. Developed healthcare systems often have specialized centers and clinics dedicated to rare diseases, such as DMD. These centers offer comprehensive care, including access to specialized healthcare professionals, physical therapy, and supportive services, which can enhance the quality of life for DMD patients.
Developed healthcare systems often provide a wide range of supportive services, such as physical and occupational therapy, assistive devices, and counselling, which can significantly enhance the quality of life for DMD patients. Governments, private investors, and philanthropic organizations are more likely to invest in drug development for rare diseases, such as DMD when there is a well-established healthcare infrastructure. This investment can support research, clinical trials, and the development of innovative therapies.
Restraint/ Challenge
- Limited Availability of DMD Treatments Due to Lack of Advance Technology
There have been limited treatment options available for DMD, leaving patients and their families with few options to slow down the progression of the disease or improve their overall well-being.
The advancement in technology often results in the development of highly specialized and innovative treatments for DMD, such as gene therapies or personalized medicine approaches. These cutting-edge therapies are complex to develop, manufacture, and administer. The development of gene therapies, in particular, involves complex processes and specialized manufacturing techniques. These therapies require the modification or replacement of faulty genes to address the underlying cause of DMD, leading to high treatment costs. In addition, the limited number of manufacturing facilities capable of producing gene therapies further contributes to their limited availability.
The complexity of advanced DMD treatments can make them challenging to manufacture and administer, further contributing to their limited availability. Specialized facilities and expertise may be required for production, and administering these treatments might demand specialized medical professionals, which can be scarce in certain regions.
Recent Developments
- In March 2023, Dyne Therapeutics announced that DYNE-251, an investigational therapeutic for Duchenne muscular dystrophy (DMD) mutations amenable to exon 51 skipping, was granted U.S. FDA orphan drug and rare pediatric disease designations. DYNE-251 is being evaluated in the Phase 1/2 DELIVER clinical trial. This helps the organization in increasing its product category and overall revenue.
- In August 2022, FibroGen, Inc. announced topline data from the Phase 3 LELANTOS-2 trial of pamrevlumab for the treatment of ambulatory patients with DMD on background systemic corticosteroids. This helped the company to strengthen its pipeline portfolio.
Global Duchenne Muscular Dystrophy Treatment Market Scope
The global duchenne muscular dystrophy treatment market is segmented into five notable segments based on treatment type, therapy, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Molecular-Based Therapies
- Steroid Therapy
- Others
On the basis of treatment type, the market is segmented into molecular-based therapies, steroid therapy, and others.
Therapy
- Exon Skipping Approach
- Mutation Suppression
- Dystrophin-Targeted Therapies
On the basis of therapy, the market is segmented into exon skipping approach, mutation suppression, and dystrophin-targeted therapies.
Route of Administration
- Oral
- Parenteral
- Others
On the basis of route of administration, the market is segmented into oral, parenteral, and others.
End User
- Hospitals
- Home Healthcare
- Specialty Clinics
- Others
On the basis of end user, the market is segmented into hospitals, home healthcare, specialty clinics, and others.
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
On the basis of distribution channel, the market is segmented into hospital pharmacy, online pharmacy, retail pharmacy.
Global Duchenne Muscular Dystrophy Treatment Market Regional Analysis/Insights
The global duchenne muscular dystrophy treatment market is segmented into five notable segments based on treatment type, therapy, route of administration, end user, and distribution channel.
The countries covered in this global duchenne muscular dystrophy treatment market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
The U.S. is expected to dominate in North America due to growing awareness and screening of DMD. Germany is expected to dominate in Europe due to rising prevalence of muscular dystrophy, and penetration of new technological advancements. China is expected to dominate Asia-Pacific as the strategic initiatives by the key market players are expanding significantly.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Duchenne Muscular Dystrophy Treatment Market Share Analysis
The global duchenne muscular dystrophy treatment market competitive landscape provides details of the competitor. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major market players operating in the global duchenne muscular dystrophy treatment market are Sarepta Therapeutics, Inc., GSK plc., Capricor Therapeutics, Inc., Dyne Therapeutics, Solid Biosciences Inc., BioMarin, Stealth BioTherapeutics Inc., Avidity Biosciences, ReveraGen BioPharma, Inc. PTC Therapeutics., NS Pharma, Inc, ITALFARMACO S.p.A., FibroGen, Inc, SANTHERA PHARMACEUTICALS, Pfizer Inc., F. Hoffmann-La Roche Ltd, Akashi RX, and TAIHO PHARMACEUTICAL CO., LTD and among others.
SKU-